SARS-CoV-2
Conditions
Interventions
Intervention: The intervention consists of Telmisartan 160 mg once daily, taken
orally for 14 days. preceded by a 2 test doses, 12 hours apart.
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Age * 70 years of age or comorbidities such as chronic lung disease, cardiovascular disease, any solid or haematological malignancies, diabetes, hypertension, rheumatic disease, immune-deficiencies either by disease or by medication use or severe obesity (BMI * 35). - Fever (a temperature of * 38,0 °C) or complaints of cough with or without dyspnoea - AND at least one of these symptoms typical for SARS-CoV-2 infection such as: o fatigue o myalgia o headache o nausea, vomiting and diarrhoea o loss of smell and/or taste. - Positive PCR test or High suspicion of a SARS-COV-2 infection because of typical symptoms and the possibility that the individuals could have been infected. - Being able to give written or verbal informed consent
Exclusion criteria
Exclusion criteria: - Suffering from (symptomatic) hypotension - Registered allergy to Telmisartan. - Receiving Potassium supplement. - Renal failure requiring dialysis therapy or (previous) kidney transplant - Known liver disease or liver insufficiency - Inability to comprehend patient information due to mental impairment such as dementia. - life expectancy of less than 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Study endpoints: The primary outcome for this study is a combination of death or hospital admission after 30 days. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are time to reduce symptoms, such as fever, cough and dyspnoe after 30 days. | — |
Countries
Netherlands
Outcome results
None listed